KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Income: 2009-2024

Historic Net Income for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $426.9 million.

  • Biomarin Pharmaceutical's Net Income fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Net Income of $426.9 million as of FY2024, which was up 154.62% from $167.6 million recorded in FY2023.
  • Biomarin Pharmaceutical's Net Income's 5-year high stood at $854.0 million during FY2020, with a 5-year trough of -$64.1 million in FY2021.
  • In the last 3 years, Biomarin Pharmaceutical's Net Income had a median value of $167.6 million in 2023 and averaged $245.4 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Net Income surged by 3,681.13% in 2020 and then plummeted by 107.50% in 2021.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Net Income stood at $854.0 million in 2020, then slumped by 107.50% to -$64.1 million in 2021, then surged by 320.91% to $141.6 million in 2022, then grew by 18.43% to $167.6 million in 2023, then soared by 154.62% to $426.9 million in 2024.